Search Within

Jedd D Wolchok

  1. "2016"
Formats
  1. Journal Article (43)
  2. Meeting Abstract (41)
Groups
  1. Department of Medicine (84)
  2. GSK Faculty (84)
  3. Melanoma and Immunotherapeutics Service (84)
  4. Solid Tumor Oncology Division (84)
  5. Melanoma Disease Management Team (24)
  6. Sloan Kettering Institute Postdocs (16)

More Groups

People
  1. Michael Postow (23)
  2. Taha Merghoub (23)
  3. Margaret Callahan (11)
  4. Phillip Wong (9)
  5. Alexander Shoushtari (8)
  6. Matthew Hellmann (8)

More People

Years
  1. 2016 (84)
Publications
  1. Journal of Clinical Oncology (18)
  2. Journal for ImmunoTherapy of Cancer (8)
  3. Cancer Immunology Research (7)
  4. Annals of Oncology (6)
  5. Clinical Cancer Research (6)
  6. Asia-Pacific Journal of Clinical Oncology (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (18)
  2. American Association for Cancer Research (15)
  3. Biomed Central Ltd (8)
  4. Elsevier Inc. (8)
  5. Oxford University Press (7)
  6. Wiley Blackwell (7)

More Publishers

Results (84)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chromatin state dynamics underlying CD8 T cell differentiation and dysfunction in cancer
    Meeting Abstract

    Philip, M.; Fairchild, L.; Sun, L.; Viale, A.; Merghoub, T.; Wolchok, J. D.; Leslie, C. S.; Schietinger, A.
    Blood (2016)

    Fulltext@MSK | Save
  • Kinase regulation of human MHC class i molecule expression on cancer cells
    Journal Article

    Brea, E. J.; Oh, C. Y.; Manchado, E.; Budhu, S.; Gejman, R. S.; Mo, G.; Mondello, P.; Han, J. E.; Jarvis, C. A.; Ulmert, D.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Ferrucci, P. F.; Hogg, D.; Atkins, M.; Wolter, P.; Guidoboni, M.; Lebbe, C.; Kirkwood, J.; Schachter, J.; Daniels, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
    Meeting Abstract

    Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma
    Meeting Abstract

    Martin-Algarra, S.; Haanen, J. B.; Horak, C.; Bhatia, S.; Ribas, A.; Hwu, W. J.; Slingluff, C. L.; Sharfman, W. H.; Callahan, M.; Hodi, F. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Meeting Abstract

    Long, G. V.; Larkin, J.; Ascierto, P. A.; Hodi, F. S.; Rutkowski, P.; Sileni, V.; Hassel, J.; Lebbe, C.; Pavlick, A. C.; Wagstaff, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: Final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
    Meeting Abstract

    Eggermont, A. M. M.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; Richards, J. M.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
    Meeting Abstract

    Forde, P. M.; Smith, K. N.; Chaft, J. E.; Hellmann, M.; Merghoub, T.; Wolchok, J. D.; Yang, S. C.; Battafarano, R. J.; Gabrielson, E.; Georgiades, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
    Journal Article

    Hodi, F. S.; Chesney, J.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; Agarwala, S. S.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients with advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Ferrucci, P.; Hogg, D.; Atkins, M.; Wolter, P.; Guidoboni, M.; Lebbe, C.; Kirkwood, J.; Schachter, J.; Daniels, G.; more...
    Asia-Pacific Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save